G1 Therapeuticslogo.JPG
G1 Therapeutics Announces New Supplemental COSELA™ (Trilaciclib) Sales Force
September 15, 2021 06:45 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Sept. 15, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it will hire and train a 15-person...
G1 Therapeuticslogo.JPG
G1 Therapeutics to Participate in Two Upcoming September Conferences
September 03, 2021 07:45 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two...
G1 Therapeuticslogo.JPG
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 03, 2021 07:30 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
G1 Therapeuticslogo.JPG
G1 Therapeutics Provides Second Quarter 2021 Financial Results and Operational Highlights
August 04, 2021 16:01 ET | G1 Therapeutics
- Achieved $6.6 Million in Total Revenue, including $2.5 Million in Net Revenue from Sales of COSELA™ (trilaciclib) - - Initiated Pivotal Phase 3 Trial in Metastatic Triple-Negative Breast Cancer...
G1 Therapeuticslogo.JPG
G1 Therapeutics Granted New Technology Add-On Payment (NTAP) for COSELA™ (Trilaciclib) by Centers for Medicare & Medicaid Services (CMS)
August 04, 2021 08:00 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Centers for Medicare &...
G1 Therapeuticslogo.JPG
G1 Therapeutics Announces Appointment of Andrew Perry as Chief Commercial Officer
August 02, 2021 06:50 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Aug. 02, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Andrew Perry as its...
G1 Therapeuticslogo.JPG
G1 Therapeutics to Provide Second Quarter 2021 Financial Results and Business Update on August 4, 2021
July 28, 2021 08:00 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., July 28, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a...
G1 Therapeuticslogo.JPG
G1 Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for COSELA™ (Trilaciclib) in Combination with Chemotherapy for the Treatment of Locally Advanced or Metastatic Triple Negative Breast Cancer
July 19, 2021 09:20 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., July 19, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the U.S. Food and Drug Administration...
G1 Therapeuticslogo.JPG
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2021 19:30 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., July 02, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
G1 Therapeuticslogo.JPG
G1 Therapeutics Announces Addition of Alicia Secor to Board of Directors
June 18, 2021 09:00 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., June 18, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Alicia Secor to its...